A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer

Inclusion Criteria: * Confirmed diagnosis of inoperable esophageal cancer(squamous cell carcinoma) * Measurable disease according to RECIST criteria * Age \> 18 years * WHO performance score \< 2 * Estimated life expectancy of \> 12 weeks * Subjects will be considered appropriate to receive systemic chemotherapy and pelvic radiotherapy * Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 10mg/dL * Renal function: Cr ≤ 1.25×UNL * Hepatic function: BIL ≤ 1.5×UNL, ALT/AST ≤ 2.5×UNL * Documented informed consent to participate in the trial Exclusion Criteria: * Subjects with distant metastases * Pregnancy or breast feeding. Women of childbearing age must use effective contraception * Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia, unstable angina, myocardial infarction, serious heart valve disease, resistant hypertension) * Evidence of bleeding diathesis or serious infection * pregnant or lactating woman * Patient participation in other studies